Kennedy Emma, Hewson Roger, Dowall Stuart
United Kingdom Health Security Agency (UKHSA), Salisbury, Wiltshire, UK.
Methods Mol Biol. 2025;2893:257-272. doi: 10.1007/978-1-0716-4338-9_19.
One of the key interventions against infection is immunization, including an increasing focus on development of vaccines against pathogenic bunyaviruses. Whilst different vaccine development approaches exist, recombinant viral vaccines have a strong safety record, are rapid to produce, are cost-effective, and have been demonstrated to be rolled out in response to outbreaks, including in low- and middle-income countries. One viral vector, modified Vaccinia Ankara (MVA), has been used to develop vaccine candidates against Crimean-Congo Haemorrhagic Fever (CCHF) virus through incorporation of the nucleoprotein (NP) and glycoprotein (GP) regions, with the former candidate having now progressed to being the first vaccine against CCHF virus to enter Phase 1 clinical trials. Herein, we report the method used to generate this MVA-based vaccine construct.
预防感染的关键干预措施之一是免疫接种，其中越来越注重开发针对致病性布尼亚病毒的疫苗。虽然存在不同的疫苗开发方法，但重组病毒疫苗具有良好的安全记录，生产速度快，具有成本效益，并且已被证明能够针对疫情进行推广，包括在低收入和中等收入国家。一种病毒载体，即改良安卡拉痘苗病毒（MVA），已被用于通过整合核蛋白（NP）和糖蛋白（GP）区域来开发针对克里米亚-刚果出血热（CCHF）病毒的候选疫苗，前一种候选疫苗现已进展到成为首个进入1期临床试验的抗CCHF病毒疫苗。在此，我们报告了用于生成这种基于MVA的疫苗构建体的方法。
